Broncodilatatore

A livello polmonare sono presenti recettori adrenergici β2 e recettori muscarinici M3. Queste proteine dimostrano effetti opposti sull'apparato respiratorio se stimolate dai legandi fisiologici (rispettivamente adrenalina e acetilcolina) o da opportune molecole di sintesi.
I recettori adrenergici vengono attivati dall'adrenalina rilasciata dalla midollare del surrene (non esiste, infatti, innervazione simpatica sui polmoni), determinando broncodilatazione e diminuzione delle secrezioni bronchiali.
I recettori colinergici, al contrario, rispondono agli stimoli del sistema parasimpatico inducendo broncocostrizione e aumentando le secrezioni.
Hanno azione adrenergica β2 anche derivati terpenici, quali il limonene, il pinene e l'eucaliptolo.
Si ricorda che, nonostante si parli di azione selettiva β2 a livello polmonare, alcuni di questi farmaci erano o sono usati per altri scopi, tra cui rilassare la muscolatura uterina ed inibire le contrazioni in caso di parto prematuro. (fonte: Wikipedia)
Comunicati Stampa

COPD Drug Market Opportunity and Clinical Pipeline Analysis

The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Some of the drugs which are major contributors to this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. By 2018, it is expected that the combinations of LABA/LAMA would the leading drugs driving sales in the COPD therapy market and by 2021, these drugs would account for more than 25% of the market share. While in 2013, close to 50% of the global market was accounted by the US, with the other regions together accounting for 50%. However, it is expected that by 2018, the share of the USA would reduce marginally to 45%, while the lost share of this region would be taken over by the Asian region. (PR Newswire - 19/04/2014) Leggi

Verona Pharma Plc ("Verona Pharma" Or The "Company") Peer-Reviewed Paper Suggests RPL554 With Glycopyrrolate, Or Other Muscarinic Receptor Antagonists, Produces Synergistic Bronchodilation

The paper suggests that inhibiting both PDE3 and 4 with RPL554 induces a larger relaxation of human bronchi than that produced by either a beta2-agonist or a muscarinic receptor antagonist. Additionally when administered with a muscarinic receptor antagonist a mixed PDE3/4 inhibitor, such as RPL554, has synergistic inhibition on airway smooth muscle tone thus affording improved bronchodilation when compared with either drug administered alone. (PR Newswire - 01/07/2013) Leggi

Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients

Novartis International AG / Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * SPARK results published in Lancet Respiratory Medicine showed that dual bronchodilator QVA149 significantly reduced the rate of moderate or severe COPD exacerbations compared to... (Thomson Reuters - 23/04/2013) Leggi

Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU

Novartis International AG / Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * Seebri® Breezhaler® 44 mcg delivered dose approved for maintenance treatment of COPD will be available to patients and physicians in some EU markets by year-end * In GLOW  trials, Seebri(®)... (Thomson Reuters - 01/10/2012) Leggi

Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149

Novartis International AG / Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * QVA149 demonstrated superior bronchodilation compared to indacaterol 150 mcg, glycopyrronium 50 mcg, salmeterol/fluticasone 50/500 mcg BID, OL tiotropium 18 mcg and placebo[1],[2] *... (Thomson Reuters - 03/09/2012) Leggi